IsoPlexis Corporation, a Branford, Conn-based life science company, raised $13.5m in its Series B financing round.
The round was led by Spring Mountain Capital, with participation by Connecticut Innovations, North Sound Ventures, and Ironwood Capital.
The company intends to use the funds for continued product development and marketing, enabling further use of the IsoCode assay and IsoLight system by trial centers and biopharmaceutical companies focused on oncology and other disease areas.
Led by Sean Mackay, Chief Executive Officer and Co-Founder, IsoPlexis is using a next-generation diagnostic and therapeutic platform to identify patient responses at the single cell level. The IsoCode assay and IsoLight can capture 42 different secreted proteins per cell, across thousands of single cells simultaneously. The result is a precise functional profile of tumor-reactive T-cells in each patient, which enables researchers to better predict and understand complex cancer patient response. The system is also being used to advance research and therapeutic development in infectious diseases, as well as multiple sclerosis, systemic lupus and other high-need areas.